PAVmed (PAVM) Sees Strong Trading Volume

PAVmed Inc (NASDAQ:PAVM) shares saw unusually-strong trading volume on Wednesday . Approximately 3,747,492 shares were traded during mid-day trading, an increase of 1,855% from the previous session’s volume of 191,659 shares.The stock last traded at $1.10 and had previously closed at $1.06.

Separately, Maxim Group reiterated a “buy” rating and issued a $3.00 target price on shares of PAVmed in a research report on Monday, January 14th.

The stock has a market capitalization of $28.77 million, a P/E ratio of -2.04 and a beta of 0.01.

A hedge fund recently raised its stake in PAVmed stock. Vanguard Group Inc boosted its stake in shares of PAVmed Inc (NASDAQ:PAVM) by 289.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 370,712 shares of the company’s stock after purchasing an additional 275,512 shares during the quarter. Vanguard Group Inc owned approximately 1.40% of PAVmed worth $482,000 at the end of the most recent reporting period. 1.97% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “PAVmed (PAVM) Sees Strong Trading Volume” was first published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at


PAVmed Inc operates as a medical device company in the United States. The company's lead product pipeline includes CarpX, a percutaneous device to treat carpal tunnel syndrome; PortIO, an implantable intraosseous vascular access device; and DisappEAR, an antimicrobial resorbable ear tube. Its product pipeline also comprises NextCath, a self-anchoring catheter; NextFlo, a disposable infusion system; and Caldus, a disposable tissue ablation device.

Read More: SEC Filing

Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with's FREE daily email newsletter.